Company intelligence / Profile preview

Evinature

Ownership: Private
Development stage: Commercial

Overview

Evinature develops evidence-based nutraceuticals—primarily the CurQD Protocol—for inflammatory bowel diseases. The company’s approach integrates gold-standard clinical research with real-world patient data. Clinical trial results show an ~85% clinical response rate and ~50% remission rate in IBD patients using their lead product. Their pipeline includes discovery-stage small molecules targeting digestive system disorders.

Therapeutic areas: Gastroenterology
Modalities: Small moleculeNutraceutical (evidence-based supplement)Herbal productNatural remedy
Industry: Biotech

Drug pipeline

1 asset

DivertX

Unknown

Partnerships

Crohn's & Colitis Foundation partnership to expand access to research-driven nutraceuticals for IBD patients in the US.Exclusive distribution deal with Adacyte Therapeutics to expand global reach of their products.

Beyond the preview

Go deeper on Evinature.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Evinature.

Explore the full profile